FORT WORTH, Texas, Nov. 13 /PRNewswire-FirstCall/ -- Wound Care
Innovations, LLC, a subsidiary of Wound Management Technologies, Inc., (OTC
Bulletin Board: WNDM), announced today the 510k clearance of a new wound
management product utilizing their patented hydrolyzed collagen technology.
The new addition to our product line (patent pending) combines hydrolyzed
collagen with the healing properties of polysulfated glycosaminoglycan (PSGAG)
and will initially be available in gel form. PSGAG enhances the absorptive
capacity of the hydrolyzed collagen gel, making it appropriate for the
management of exudative wounds. In addition, PSGAG has been shown to prepare
the granulation tissue for epidermal migration by maintaining a uniform, low
density granulation tissue more easily modified by the migrating epithelium
thus improving the rate of epithelialization of a chronic wound and reducing
scarring.
The product has been cleared and is indicated for topical use in the
management of chronic and acute wounds and dermal ulcers including the
management of:
-- Pressure Ulcers (Stages I-IV)
-- Venous Stasis Ulcers
-- Diabetic Ulcers
-- First and Second Degree Burns
-- Surgical Wounds
-- Traumatic wounds
-- Superficial Wounds
-- Ulcers resulting from arterial insufficiency
-- Grafted wounds and donor sites
"We are delighted with the FDA clearance of the hydrolyzed collagen with
polysulfated glycosaminoglycan (PSGAG)," states Cathy Bradshaw, President of
Wound Care Innovations. "This allows us to bring to the high margin, advanced
wound care market, a product that utilizes our proven, patented hydrolyzed
collagen and incorporates the distinctive characteristics of PSGAG to prepare
the wound bed for re-epithelialization, wound closure."
Costs associated with wound care are significant, exceeding billions of
dollars annually. "We are introducing a new, improved product which addresses
the epithelialization of healing wounds and will be cost effective, patient
ready and easy to use in all health care settings. The product is cost
effective both in terms of direct and indirect costs. We are encouraged by
initial test observations which promise improved clinical outcomes for the
patient. Our expectations are high. We expect our hydrolyzed collagen with
Polysulfated Glycosaminoglycan to contribute significantly to our growth
moving forward."
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM), with its
corporate headquarters in Fort Worth, Texas, markets and distributes wound
care products to the healthcare market under patented technology licensed to
the Company. The Company is positioned and seeks to be a leading provider of
wound care products. For more information on the Company please visit the
Company's Website at www.Celleraterx.com .
"Safe Harbor" Statement: Under The Private Securities Litigation Reform
Act of 1995: The statements in the press release that relate to the company's
expectations with regard to the future impact on the company's results from
new products in development are "forward-looking statements," within the
meaning of the Private Securities Litigation Reform Act of 1995. Since this
information may contain statements that involve risk and uncertainties and are
subject to change at any time, the company's actual results may differ
materially from expected results. This document may contain forward-looking
statements concerning the Company's operations, current and future performance
and financial condition. These items involve risks and uncertainties such as
product demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and integrate
acquisitions, and other risks and uncertainties detailed in the Company's SEC
filings. The Company undertakes no obligation to revise any of these
statements to reflect the future circumstances or the occurrence of
unanticipated events.
For Further Information:
Product Information Shareholder Relations
Cathy Bradshaw Lucy Singleton
President Secretary
954-315-9242 817-820-7080
SOURCE Wound Management Technologies, Inc.
